Quantcast

ProMIS offeri potential significant advantage over aducanumab, learns from mistakes

ProMIS Neurosciencesissued a pres release Friday, raising urgency to selectively target the toxic oligomer with exacting precision as part of the global effort to develop disease-modifying therapies for Alzheimer’s disease (AD), upon Biogen’s and Eisai’s dropping two alte-stage clinical trials of aducanumab.

Read more